Accera Joins Alzheimer's Association Research Roundtable

BROOMFIELD, Colo., Sept. 21, 2015 /PRNewswire/ -- Accera, Inc., a clinical-stage biotechnology company developing therapies for central nervous system disorders, announced today that it has been invited to join the Alzheimer's Association Research Roundtable. Participation in the Roundtable provides an opportunity for the company to advance Alzheimer's disease research and drug development by sharing scientific knowledge with other major research organizations in the field. Accera executives will participate in Roundtable presentations and related subcommittee meetings, with a particular focus on the need for new treatments for Alzheimer's disease.

"Alzheimer's disease is a major public health concern, and the lack of new treatments has significantly impacted the lives of patients and family members," said Accera's president and CEO, Dr. Charles Stacey. "The development of new treatments is desperately needed. We share the goal of the Alzheimer's Association of advancing treatments and look forward to working with the other Roundtable member companies."

The Alzheimer's Association Research Roundtable is a consortium of scientists from the pharmaceutical, biotech, diagnostics, imaging and cognitive testing industries along with Association staff and advisors. The Research Roundtable's mission is to facilitate the development and implementation of new treatments for Alzheimer's disease by collectively addressing obstacles to research and development, clinical care, and public health education.

"Our participation in the Research Roundtable will allow us to engage in the dialogue about late-stage clinical trials in Alzheimer's disease that is crucial to moving this indication forward," added Samuel Henderson, Ph.D., Accera's vice president of research and development and the director of Accera's Phase 3 NOURISH AD trial for patients with mild to moderate Alzheimer's disease. "Because of the many common and well-known challenges in Alzheimer's drug development, we hope that our participation in this initiative will help broaden the types of therapies that are tested in the clinic and contribute to a higher rate of success in the field."

About the NOURISH AD Phase 3 Clinical Study

NOURISH AD is a 26-week, double-blind, randomized, placebo-controlled, parallel-group study investigating the effects of daily administration of AC-1204 in subjects with mild to moderate Alzheimer's disease, with an optional 26-week open-label extension. Conducted at up to 90 sites, the study is currently enrolling patients with an anticipated total of approximately 480 enrolled. The primary and key secondary endpoints will examine the effects of AC-1204 on memory and cognition as measured by the Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-Cog) and global function as measured by the Alzheimer's Disease Study Cooperative Study – Clinical Global Impression of Change (ADCS-CGIC) after 26 weeks among non-carriers of the epsilon 4 variant of the gene apolipoprotein E (APOE4). The study will also evaluate activities of daily living, resource utilization and quality of life among subjects with mild to moderate Alzheimer's.

For more information, visit http://www.ad-trial.com.

About Accera

Accera, Inc. is a clinical-stage biotechnology company based in Broomfield, Colorado, developing therapies for central nervous system disorders. The company's proprietary scientific platform addresses unmet medical needs in brain health, including Alzheimer's disease. Accera is focused on the clinical development of drugs with innovative mechanisms of actions. The company's management team includes globally recognized specialists in central nervous system diseases and drug development, who together leverage the latest scientific knowledge and understanding of neurological disorders. Accera's lead product candidate is AC-1204, a ketosis-inducing compound in a Phase 3 clinical study in patients with mild to moderate Alzheimer's disease.

For more information, visit www.accerapharma.com. Follow Accera on Twitter at twitter.com/accerainc.

Accera Media Contacts:
Russo Partners LLC

Todd Davenport, Ph.D.
(212) 845-4235
[email protected]

David Schull
(212) 845-4271
(858) 717-2310 Mobile
[email protected]

SOURCE Accera, Inc.

Related Links

http://www.accerapharma.com